EN DE
Watch Amylyx Pharmaceuticals Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Amylyx Pharmaceuticals Inc (AMLX) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Amylyx Pharmaceuticals Inc stock $21.08, price $30.91, that is 31.8% below the price, quality 41 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

AP Amylyx Pharmaceuticals Inc logo Thin data Nov 11, 2026

Amylyx Pharmaceuticals Inc

AMLX · US
Expensive, weak quality

Our calculation puts a fair price 32% below what the stock costs today.

Positive coverage
Quality 41/100
Mixed Growth (revenue 5y +127.7 %/yr in USD)
Insiders bought $51,338 (6M) · sold $4.3M
Fair value $21.08 · Overvalued
Negative free cash flow
Trails peers (0/6)
Narrow moat 8/100 · thin data
Thin data
Estimate
Watch Amylyx Pharmaceuticals Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$40.93 $1.62 Fair Value $21.08 Jan 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

58‑month range $1.62 – $40.93 · fair‑value band $15.81 – $26.35 · the $30.91 price screens above the $21.08 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.

Follow Amylyx Pharmaceuticals in your weekly email

Every Wednesday you see whether Amylyx Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.

Show moreShow less

It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.

The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases.

Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Stock analysis

Amylyx Pharmaceuticals Inc (AMLX) currently trades at $30.91, while our estimate is $21.08, 32% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $15.81 (bear) to $26.35 (bull), the price of $30.91 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Amylyx Pharmaceuticals Inc reported revenue of $0 in FY2025 versus $285K in FY2021. Reported net income was −$145M in FY2025.

Key figures

Market cap $3.9B Mid · EPS (TTM) $−1.43 · Return on equity −30.1% · Return on assets (EBIT) −66.2% (5-year average) · Revenue (TTM) −$665K · Free cash flow −$123M · Net cash $221M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 22% below its 52-week high and 172% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −32%, AMLX screens richer than that median.

Fair Value

Bear $15.81 Fair Value $21.08 Bull $26.35
Price $30.91 · Downside -31.8%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 41/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 33
Are margins and returns getting better?
Cashflow 24
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 97
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 85
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director bought shares worth $51,338, on May 21, 2026. Over the same period, 6 people sold shares worth $4.3M.

  • SaleGeorge M Milne JrDirector30,000 shares at $27.70$830,904Oct 5, 202610b5-1 plan
  • SaleJustin B. KleeCo-Chief Executive Officer, Director5× since Jan 6, 2026: 221,149 shares, avg. $16.25$3.6MSep 10, 2026
  • SaleJoshua B CohenCo-Chief Executive Officer, Director5× since Jan 6, 2026: 221,128 shares, avg. $16.26$3.6MSep 10, 2026
  • SaleGina MazzarielloChief Legal Officer5× since Feb 2, 2026: 53,247 shares, avg. $19.66$1.0MSep 10, 2026
  • SaleJames M FratesChief Financial Officer4× since Jan 6, 2026: 25,602 shares, avg. $21.63$553,740Sep 10, 2026
  • SaleCamille L BedrosianChief Medical Officer3× since Dec 1, 2025: 23,069 shares, avg. $22.26$513,458Sep 10, 2026
  • BuyKaren FirestoneDirector2× since Dec 23, 2025: 11,900 shares, avg. $12.79$152,183May 21, 2026

Plus 6 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 28/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−77.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+574.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+127.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−950.5% (2019) → −360.2% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

AMLX screens overvalued: fair value 32% below the price. Compare with Merck KGaA →

Recent news

News mood ⓘNews mood, the average tone of recent news (92 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.

Compare Amylyx Pharmaceuticals Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 606 stocks

Beats the industry median on 0/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 41 · Bottom 25%
Fair Value upside −31.8% · Below median
Profitability
Return on assets −43.5% · Bottom 25%
Operating margin (12 months) 0.0% · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 12.72× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.46 $113.53 +38% vs AMLX
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.55 ¥55.21 +14% vs AMLX
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,905 ₹1,983 +4% vs AMLX
Haleon plc HLN $9.06 $8.62 −5% vs AMLX
Merck KGaA MRK €149.35 €109.18 −27% vs AMLX
Galderma Group GALD CHF 188.55 CHF 109.80 −42% vs AMLX
Takeda Pharmaceutical Company TAK $20.93 $11.34 −46% vs AMLX
Teva Pharmaceutical Industries Limited TEVA $42.40 $20.74 −51% vs AMLX
Sandoz Group SDZ CHF 83.38 CHF 39.70 −52% vs AMLX
Divi's Laboratories Limited DIVISLAB ₹11,566 ₹1,567 −86% vs AMLX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Amylyx Pharmaceuticals Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Amylyx Pharmaceuticals Inc Fair Value". https://www.fairvalue-calculator.com/stock/AMLX

Frequently asked questions

Is Amylyx Pharmaceuticals Inc (AMLX) overvalued or undervalued?
As of Nov 11, 2026, our estimate of fair value is $21.08 versus a price of $30.91, about 32% lower (overvalued).
What is the fair value of AMLX?
Our estimate for Amylyx Pharmaceuticals Inc is $21.08 (as of Nov 11, 2026), built from audited fundamentals. The current price: $30.91.
What is the quality score of AMLX?
Amylyx Pharmaceuticals Inc has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Amylyx Pharmaceuticals Inc (AMLX)?
Our calculated price target is the estimate of $21.08 (as of Nov 11, 2026). Cautious scenario $15.81, optimistic scenario $26.35. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Amylyx Pharmaceuticals Inc stock forecast for 2026?
Our estimate puts fair value at $21.08, about 32% lower versus a price of $30.91 (overvalued). Cautious scenario $15.81, optimistic scenario $26.35. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Amylyx Pharmaceuticals Inc (AMLX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Amylyx Pharmaceuticals Inc it is $21.08 per share (as of Nov 11, 2026), against a price of $30.91.
Is Amylyx Pharmaceuticals Inc stock overvalued or undervalued in 2026?
As of Nov 11, 2026, AMLX trades above its calculated fair value: price $30.91, fair value $21.08, a gap of about −32% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AMLX?
No. The price is what the market pays today ($30.91); the fair value is what the company's own numbers justify ($21.08). For Amylyx Pharmaceuticals Inc the two are $9.83 per share apart. That gap is exactly why we show both numbers side by side.
How much is Amylyx Pharmaceuticals Inc worth?
The market values Amylyx Pharmaceuticals Inc at about $3.9B (market capitalisation, as of Nov 11, 2026). Per share that is $30.91; our models calculate a fair value of $21.08 per share.
What do the bullish and bearish scenarios say about AMLX?
Our models span a range for Amylyx Pharmaceuticals Inc: cautious scenario $15.81, base $21.08, optimistic $26.35 per share (as of Nov 11, 2026, price $30.91). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Amylyx Pharmaceuticals Inc (AMLX)?
Balance-sheet figures for Amylyx Pharmaceuticals Inc (as of Nov 11, 2026): return on equity −30.1%. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is AMLX from its 52-week high?
Amylyx Pharmaceuticals Inc trades at $30.91, about 22% below its 52-week high of $39.66 and 172% above the low of $11.38 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $21.08 is for.
Which stocks are comparable to Amylyx Pharmaceuticals Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Amylyx Pharmaceuticals Inc stock attractive at the current price?
The data as of Nov 11, 2026: price $30.91, calculated fair value $21.08 (−32%), Quality Score 41/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Amylyx Pharmaceuticals Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Amylyx Pharmaceuticals Inc (AMLX)?
The closing price on Nov 10, 2026 was $30.91. Our estimate is $21.08, about 32% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Amylyx Pharmaceuticals Inc right now?
The price sits above even our optimistic bull case ($26.35). The favourable scenario is already priced in. Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Amylyx Pharmaceuticals Inc

How large is the market capitalisation of Amylyx Pharmaceuticals Inc (AMLX)?
The market capitalisation of Amylyx Pharmaceuticals Inc is $3.9B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Amylyx Pharmaceuticals Inc (AMLX)?
Earnings per share at Amylyx Pharmaceuticals Inc are $−1.43. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Amylyx Pharmaceuticals Inc (AMLX)?
The return on equity (ROE) of Amylyx Pharmaceuticals Inc is −30.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Amylyx Pharmaceuticals Inc (AMLX)?
On an EBIT basis the return on assets of Amylyx Pharmaceuticals Inc is −66.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much revenue does Amylyx Pharmaceuticals Inc (AMLX) generate?
Amylyx Pharmaceuticals Inc generates revenue of −$665K (last twelve months). Revenue of the last twelve months (TTM), the most recent full year, not the calendar year.
How much free cash flow does Amylyx Pharmaceuticals Inc (AMLX) generate?
The free cash flow of Amylyx Pharmaceuticals Inc is −$123M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Amylyx Pharmaceuticals Inc (AMLX) hold?
Amylyx Pharmaceuticals Inc holds more cash than debt, $221M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Amylyx Pharmaceuticals Inc in the live analysis

One click puts Amylyx Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.